2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. Ribosomal S6 Kinase (RSK)
  5. RSK3 Isoform

RSK3

RSK3 (ribosomal S6 kinase 3; RPS6KA2) is a serine/threonine kinase of the p90RSK family that contains two functional kinase domains and acts downstream of ERK/MAPK signaling to regulate cellular growth, differentiation, and transcriptional responses[1][2]. Mechanistically, RSK3 integrates extracellular growth-factor signals through ERK-dependent activation and participates in MAPK-controlled signaling networks that influence gene expression and adaptive cellular programs[1][3]. Through this position in the ERK pathway, RSK3 contributes to biological processes linked to cellular remodeling and stress responses, making it relevant for studies of signal transduction and kinase-regulated phenotypes[2][3]. In disease-related models, RSK3 has been identified as a required mediator of pathological cardiac myocyte hypertrophy, and experimental evidence indicates that RSK3-dependent signaling modulates pathological myocardial growth and cardiac remodeling[4][5]. Compared with related RSK isoforms, RSK3 possesses a unique N-terminal sequence that distinguishes it from other family members and has been associated with specific subcellular localization and signaling properties, supporting isoform-selective biological functions[1]. This isoform-specific behavior is particularly important when dissecting ERK-effector pathways because phenotypes attributed to total RSK activity may depend on RSK3-mediated signaling mechanisms[5]. For experimental applications, pharmacological targeting of the RSK family is widely used to interrogate ERK-RSK signaling, and RSK-directed inhibitors provide useful tools for studying RSK3-associated pathways in disease and cellular signaling models[3].

RSK3 관련 제품 (6):

Cat. No. 상품명 효과 Purity
  • HY-10510
    BI-D1870
    		Inhibitor 99.43%
    BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of RSK isoforms, with IC50s of 31 nM/24 nM/18 nM/15 nM for RSK1/RSK2/RSK3/RSK4, respectively.
  • HY-19713
    LJI308
    		Inhibitor 99.07%
    LJI308 is a potent pan-ribosomal S6 kinase (RSK) inhibitor, with IC50s of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. LJI308 inhibits the phosphorylation of RSK (T359/S363) and YB-1 (S102) after irradiation, treatment with EGF, and in cells expressing a KRAS mutation.
  • HY-10579
    Pluripotin
    		Inhibitor 98.86%
    Pluripotin is a dual inhibitor of ERK1 and RasGAP with KDs of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC50s of 0.5, 2.5, 3.3, and 10.0 μM, respectively.
  • HY-12185
    BRD7389
    		Inhibitor 99.06%
    BRD7389 is a specific RSK family kinase inhibitor with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 is a small-molecule inducer of insulin expression in pancreatic α-cells.
  • HY-173406
    RSK-IN-2
    		Inhibitor 99.32%
    RSK-IN-2 (Compound 3e) is a RSK inhibitor, with IC50 s of 37.89 nM (RSK2), 30.78 nM (RSK1), 20.51 nM (RSK3), 91.28 nM (RSK4). RSK-IN-2 inhibits tumor cell proliferation, induces apoptosis and causes cell cycle arrest in the G2/M phase.
  • HY-150643
    RSK2-IN-2
    		Inhibitor
    RSK2-IN-2 (Compound 25) is a reversible covalent inhibitor of the RPS6KA3 (RSK2) kinase. RSK2-IN-2 is also described to inhibit MSK1, MSK2 and RSK3.
Cat. No. 상품명 / Synonyms Application Reactivity